Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma.


Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
May 2022
Historique:
received: 03 07 2021
accepted: 10 09 2021
pubmed: 25 9 2021
medline: 21 4 2022
entrez: 24 9 2021
Statut: ppublish

Résumé

Resistance to radiation therapy (RT) remains an obstacle in HPV-negative head and neck squamous cell carcinomas (HNSCCs)-even with a combined RT-immunotherapy approach. Jak-Stat proteins have long been studied for both their immune regulatory role in the host immune response as well as their cancer cell signaling role in shaping the tumor microenvironment (TME). Here, we identify STAT1 as a mediator of radioresistance in HPV-negative preclinical mouse models of HNSCC, by which knockout of STAT1 in the cancer cell (STAT1 KO)-but not in the host-resulted in decreased tumor growth alongside increased immune activation. We show that RT increases STAT1/pSTAT1 expression, which may act as a marker of radioresistance. Whereas RT increased JAK-STAT and interferon (IFN) signaling, transcriptomic analysis revealed that STAT1 KO in the cancer cell resulted in decreased expression of IFN-associated genes of resistance. In vitro experiments showed that STAT1 KO increased T cell chemoattraction and decreased baseline growth. These results indicate that STAT1 may serve a tumor-promoting role in the cancer cell and will inform biomarker development and treatment regimens for HNSCC incorporating RT.

Identifiants

pubmed: 34559306
doi: 10.1007/s00262-021-03059-3
pii: 10.1007/s00262-021-03059-3
pmc: PMC9987617
mid: NIHMS1866752
doi:

Substances chimiques

STAT1 Transcription Factor 0
STAT1 protein, human 0
Stat1 protein, mouse 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1049-1061

Subventions

Organisme : NCI NIH HHS
ID : P50 CA261605
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028529
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046934
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028282
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028529-01
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028282-01
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Int J Cancer. 2020 Mar 15;146(6):1717-1729
pubmed: 31709529
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842362
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
J Cell Physiol. 2020 Sep;235(9):5903-5924
pubmed: 32072644
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1714-9
pubmed: 14755057
Nat Immunol. 2017 Mar 22;18(4):374-384
pubmed: 28323260
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Curr Protoc Cytom. 2010 Jul;Chapter 10:Unit10.17
pubmed: 20578106
Clin Cancer Res. 2018 Sep 15;24(18):4539-4550
pubmed: 29848571
Cancer Res. 2007 Oct 1;67(19):9214-20
pubmed: 17909027
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33883256
Eur J Immunol. 2003 Aug;33(8):2241-50
pubmed: 12884299
J Cell Physiol. 2020 Dec;235(12):9121-9132
pubmed: 32401349
Cytokine. 2017 Jan;89:12-20
pubmed: 26631912
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
J Oral Pathol Med. 2009 Nov;38(10):759-63
pubmed: 19453846
Cell. 2019 Aug 8;178(4):933-948.e14
pubmed: 31398344
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Clin Cancer Res. 2018 Nov 1;24(21):5368-5380
pubmed: 30042205
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548

Auteurs

Michael W Knitz (MW)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Laurel B Darragh (LB)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Thomas E Bickett (TE)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Shilpa Bhatia (S)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Sanjana Bukkapatnam (S)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Jacob Gadwa (J)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Miles Piper (M)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Sophia Corbo (S)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Diemmy Nguyen (D)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Benjamin Van Court (B)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA.

Ayman Oweida (A)

Départment de Médecine Nucléaire et Radiobiologie, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Sana D Karam (SD)

Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, Colorado, 80045, USA. sana.karam@cuanschutz.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH